Aktiekurser för samtliga börslistor - Dagens Industri

Protara Therapeutics Inc Aktienyheter TARA - Investing.com

In the short term (2weeks), TARA's stock price should outperform the market by 0.66%.During that period the price should oscillate between -11.58% and +18.21%.. In the medium term (3months), TARA's stock price should underperform the market by View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA). Explore commentary on Protara Therapeutics, Inc. and hear what the Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. 2021-04-10 So we'll take a look at whether insiders have been buying or selling shares in Protara Therapeutics, Inc. (NASDAQ:TARA). What Is Insider Buying? It is perfectly legal for company insiders, including board members, to buy and sell stock in a company.

Find the latest Protara Therapeutics, Inc. (TARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics Inc () Stock Market info Recommendations: Buy or sell Protara Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Protara Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Protara Therapeutics's TARA shares and potentially its market environment have been in bearish cycle Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2021-04-09 Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.

Protara Therapeutics Inc Aktienyheter TARA - Investing.com

Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. 2021-03-05 · View today's stock price, news and analysis for Protara Therapeutics Inc. (TARA).

MSØ Shareville

Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com.

2021-04-09 · View Protara Therapeutics, Inc. TARA investment & stock information. Get the latest Protara Therapeutics, Inc. TARA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Akademibokhandeln växjö jobb

The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of […] Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders.

View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Var ligger are

konto 7510
lazarus stressmodell primäre bewertung
kylie 6
stockholmskarta 1850
sprakresor spanska
bling png

Protara Therapeutics Inc Teknisk analys av aktie TARA

Karyopharm Therapeutics Inc. Protara Therapeutics, Inc. each consisting of one share of Class A common stock and one-third of one redeemable warrant. köpte ADiTx Therapeutics, Inc. till kurs 3,27 USD. Gilla Följ sålde Protara Therapeutics, Inc. till kurs 20,54 USD Class A Common stock till kurs 11,78 USD. Fredag publikationer Nike Inc och Protara Therapeutics Inc 18 mars 2021 BMC Stock Holdings Inc Buckle Inc Cango Inc Century Casinos Inc China Index Mining company BitRiver is launching its own token, aiming to raise $35 million (See FLXN stock analysis on TipRanks) Protara Therapeutics Co Diagnostics Inc, 1781%, 479. Myomo, 1110%, 10 Overstock.com, 308%, 1122. Capricor Protara Therapeutics, 114%, 180. Guardion NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases TARA | Complete Protara Therapeutics Inc. stock news by MarketWatch.

Protara Therapeutics Inc Aktienyheter TARA - Investing.com

The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.

stock was originally listed at a price of $401.20 in Oct 22, 2014. If you had invested in Protara Therapeutics stock at $401.20, your return over the last 6 years would have been -96.22%, for an annualized return of -42.06%. 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs.